Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), humans have been exposed to distinct SARS-CoV-2 antigens, either by infection with different variants, and/or vaccination. Population immunity is thus highly heterogeneous, but the impact of such heterogeneity on the effectiveness and breadth of the antibody-mediated response is unclear. We measured antibody-mediated neutralization responses against SARS-CoV-2Wuhan, SARS-CoV-2α, SARS-CoV-2δ, and SARS-CoV-2ω pseudoviruses using sera from patients with distinct immunological histories, including naive, vaccinated, infected with SARS-CoV-2Wuhan, SARS-CoV-2α, or SARS-CoV-2δ, and vaccinated/infected individuals. We show that the breadth and potency of the antibody-mediated response is influenced by the number, the variant, and the nature (infection or vaccination) of exposures, and that individuals with mixed immunity acquired by vaccination and natural exposure exhibit the broadest and most potent responses. Our results suggest that the interplay between host immunity and SARS-CoV-2 evolution will shape the antigenicity and subsequent transmission dynamics of SARS-CoV-2, with important implications for future vaccine design.

Keywords. SARS-CoV-2; antibody-mediated immunity; immunological history; virus evolution; virus neutralization.

Lay Summary. Neutralizing antibodies provide protection against viruses and are generated because of vaccination or prior infections. The main target of anti-SARS-CoV-2 neutralizing antibodies is a protein called spike, which decorates the viral particle and mediates viral entry into cells. As SARS-CoV-2 evolves, mutations accumulate in the spike protein, allowing the virus to escape antibody-mediated immunity and decreasing vaccine effectiveness. Multiple SARS-CoV-2 variants have appeared since the start of the COVID-19 pandemic, causing various waves of infection through the population and infecting— in some cases—people that had been previously infected or vaccinated. Because the antibody response is highly specific, individuals infected with different variants are likely to have different repertoires of neutralizing antibodies. We studied the breadth and potency of the antibody-mediated response against different SARS-CoV-2 variants using sera from vaccinated people as well as from people infected with different variants. We show that potency of the antibody response against different SARS-CoV-2 variants depends on the particular variant that infected each person, the exposure type (infection or vaccination) and the number and order of exposures. Our study provides insight into the interplay between virus evolution and immunity, as well as important information for the development of better vaccination strategies.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 [1] causing the largest pandemic of the 21st century. Since the start of the pandemic, different viral lineages emerged, exhibiting highly dynamic transmission patterns [2–5]. This is illustrated by the epidemiology of coronavirus disease 2019 (COVID-19) in the United Kingdom since the first introduction of SARS-CoV-2 in late February 2020, when the Wuhan strain (SARS-CoV-2W) was first reported. A D614G variant of the Wuhan strain circulated almost exclusively until September of the same year, when the Alpha strain (SARS-CoV-2α) appeared, initially in the southeast of England [2]. By December 2020, SARS-CoV-2α was the dominating variant. At this point in time, the United Kingdom started a COVID-19 vaccination program that took place with unprecedented pace: by 1 July 2021, approximately 47 million people (mainly adults) had received at least 1 vaccine dose [6]. However, during this period, a new variant (Delta, SARS-CoV-2δ) emerged in India, reaching the United Kingdom in April 2021, and quickly became the most prevalent lineage, until November 2021, when the Omicron variant
(SARS-CoV-2o) was introduced and quickly replaced SARS-CoV-28. Over a period of approximately 2 years (February 2020 to March 2022) the UK population experienced 4 COVID-19 pandemic waves, each of them caused by a different SARS-CoV-2 variant (Wuhan, Alpha, Delta, and Omicron). In addition, SARS-CoV-28 and SARS-CoV-2o infections have been reported in individuals that had been previously vaccinated or infected by preceding variants [7, 8]. As a result, population immunity against SARS-CoV-2 is likely to be highly heterogeneous. The impact of such immunological heterogeneity on SARS-CoV-2 fitness is far from clear. As antibody-mediated immunity is considered a correlate of protection [9, 10], identifying the factors that affect the humoral immune response is key for COVID-19 preparedness and to design more effective vaccines. Our overall objective was to quantify the breadth and potency of antibodies elicited by different immune histories against distinct SARS-CoV-2 variants. To this end, we measured antibody-mediated immunity against SARS-CoV-2W, SARS-CoV-2a, SARS-CoV-28, and SARS-CoV-2o using convalescent serum samples from the Glasgow patient population collected between 31 March 2020 and 22 September 2021. Our sampling strategy captured the complex immunological landscape described above and included sera from naïve, vaccinated, infected, as well as vaccinated and infected individuals. Importantly, by combining patient metadata (date of positive polymerase chain reaction [PCR]) with virus genomic epidemiology (prevalence of circulating lineages over time) we were able to select confidently serum samples from patients exposed to 3 major variants that circulated in the United Kingdom (Wuhan, Alpha, and Delta).

**METHODS**

**Ethics Statement**

Ethical approval was provided by National Health Service Greater Glasgow and Clyde (NHSGGC) Biorepository (application 550).

**Serum Samples**

Random residual biochemistry serum samples (approximately 41,000) from primary (general practices) and secondary (hospitals) health care settings were collected by the NHSGGC Biorepository between the 31 March 2020 and 22 September 2021. Associated metadata included age, care type, date of sample collection, date of positive PCR result, date of first and second vaccination, and vaccine manufacturer. Seronegative samples were selected based on their enzyme-linked immunosorbent assay (ELISA) results (SARS-CoV-2 spike 1 [S1] or SARS-CoV-2 receptor-binding domain [RBD]) and the absence of a positive PCR test result or record of vaccination. Samples from vaccinated patients were selected based on their ELISA result (SARS-CoV-2 S1 or SARS-CoV-2 RBD), record of vaccination with 1 or 2 doses at least 14 days prior to blood collection, and absence of a positive PCR test result for at least 14 days after sampling. Samples from infected patients had no record of vaccination, were ELISA positive (SARS-CoV-2 S1 or SARS-CoV-2 RBD), and had a positive PCR test result at least 14 days before sample collection. Samples from infected and vaccinated patients were identified by their positive ELISA result, the presence of positive PCR test result and record of vaccination with 1 or 2 doses at least 14 days prior to blood collection. Samples from infected and vaccinated patients were further stratified to infecting variants (based on the date of the positive PCR test), by identifying key time periods during which each variant was most predominant. All serum samples were inactivated at 56°C for 30 minutes before being tested.

**Cells**

HEK293T and 293-ACE2 cells were maintained at 37°C, 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 μg/mL streptomycin, and 100 IU/mL penicillin. HEK293 cells were used to produce HEK293-ACE2 target cells by stable transduction with pSCRPSY-hACE2 and were maintained in complete DMEM supplemented with 2 μg/mL puromycin. HEK293T cells were used for the generation of human immunodeficiency virus (HIV) (SARS-CoV-2) pseudotypes.

**IgG Quantification**

Immunoglobulin G (IgG) antibodies against SARS-CoV-2 spike and nucleocapsid proteins were measured using an MSD V-PLEX COVID-19 Coronavirus Panel 2 (K15369) kit. Multiplex Meso Scale Discovery electrochemiluminescence (MSD-ECL) assays were performed according to the manufacturer’s instructions. Briefly, 96-well plates were blocked at room temperature for at least 30 minutes. Plates were then washed; samples were diluted 1:5000 and added to the plates along with serially diluted reference standard and serology controls. Plates were incubated for 2 hours and further washed. SULFO-TAG detection antibody was added, and plates were incubated for 1 hour. After incubation, plates were washed and read using a Meso Sector S 600 plate reader. Data were generated by Methodological Mind software and analyzed using MSD Discovery Workbench (version 4.0). Results were normalized to standard(s) and expressed as MSD arbitrary units per mL (AU/mL).

**Neutralization Assays**

Pseudotype-based neutralization assays were carried out as described previously [11]. HEK293T cells were transfected with the appropriate SARS-CoV-2 spike gene expression vector (Wuhan, Alpha, Delta, or Omicron) together with p8.9171 and pCSFLW72 using polyethylenimine (Polysciences). HIV (SARS-CoV-2) pseudotype-containing supernatants were harvested 48 hours posttransfection, aliquoted, and frozen at –80°C prior to use. Gene constructs bearing the Wuhan (D614G),
Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) spike genes were based on the codon-optimized spike sequence of SARS-CoV-2 and generated by GenScript Biotech. Constructs bore the following mutations relative to the Wuhan-Hu-1 sequence (GenBank: MN908947): Wuhan(D614G), D614G; Omicron (BA.1, B.1.1.529), A67V, Δ69–70, T95I, G142D/Δ143–145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G466S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F; Alpha (B.1.1.7), L18F, A69–70, Δ144, N501Y, A570D, P681H, T716I, S982A, D1118H; and Delta (B.1.617.2), T19R, G142D, Δ156–157, R158G, L452R, T478K, D614G, P681R, D950N.

Neutralization efficiency was measured first using a fixed dilution of serum samples in duplicates. Samples with neutralizing activity ≥ 50% relative to the no serum control were then titrated by serial dilutions. Each sample was serially diluted in triplicate from 1:50 to 1:36 450 in complete DMEM, incubated for 1 hour with HIV (SARS-CoV-2) pseudotypes, and plated onto HEK239-ACE2 target cells. After 48 hours, luciferase activity was measured by adding Steadylite Plus chemiluminescence substrate and analyzed using a Perkin Elmer EnSight multimode plate reader. Antibody titers were estimated by interpolating the point at which infectivity had been reduced to 50% of the value for the no serum control samples. Samples that did not have an antibody titer were arbitrary assigned a value of 50 (the lowest dilution available).

Statistical Analysis
Shapiro-Wilk tests were performed to assess data homoscedasticity. As data were found not to be normally distributed, nonparametric pairwise Wilcoxon rank sum tests were carried out to assess statistically significant differences in antibody levels between groups and viruses. Holm’s method was used to adjust P values to account for multiple statistical comparisons. Separate tests were performed for each group when comparing between viruses, and for each virus when comparing between groups. Pairwise comparisons were presented as connected dot plots, highlighting the significance levels of each of the paired comparisons. All analyses and data visualizations were executed using the stats [12] and ggplot2 [13] packages, respectively, from R version 4.0.5.

Data Availability
Data of each sample, including metadata and results of each assay, are included in the Supplementary Material.

RESULTS
A schematic description of the study is shown in Figure 1. Out of the 353 biobanked sample have been collected for serological surveillance studies [11] were selected. The immunological history of each patient at the time of sampling was compiled based on serological status using an ELISA assay that tested for SARS-CoV-2 spike 1 (S1) and receptor binding domain (S1-RBD) [11] together with metadata associated with each clinical specimen. Associated metadata consisted of date of serum collection, SARS-CoV-2 PCR status (including date and result of diagnosis), and vaccination status (including date of vaccination and number of doses). Samples were initially classified in 4 broad groups: naive (N, 30 samples), vaccinated (V, 55 samples) infected (I, 91 samples), and infected and vaccinated (IV, 177 samples). Further, sera from the I and IV group were stratified based on the infecting variant as infected-Wuhan (I\(_W\), 37 samples), infected-Delta (I\(_\delta\), 39 samples), infected-Delta-vaccinated (I\(_W\delta\), 48 samples). The date of PCR confirmation and the prevalence of each variant at the time of diagnosis was used to infer the most likely infecting variant (see “Methods” section and Supplementary Figure 1). All serum samples were processed as follows: first, they were tested using a multiplex electrochemiluminescence assay against the spike (S), and nucleocapsid (N) proteins to quantify antibody concentrations. Further, serum samples were subjected to virus neutralization assays [11] at a fixed dilution (1:50) using pseudotypes carrying the S glycoprotein of either SARS-CoV-2\(_{\delta}\), SARS-CoV-2\(_W\), SARS-CoV-2α, or SARS-CoV-2δ. Samples that displayed 50% neutralization to at least 1 SARS-CoV-2 variant were titrated as previously described [13].

Quantification of S and N antibody levels for each group of patients is shown in Figure 2. As expected, sera from patients in the naive group (neither vaccinated nor infected) exhibited the lowest levels of anti-S antibodies because they had not been exposed to the spike antigen of SARS-CoV-2. Patients that had been infected displayed higher levels of anti-S antibodies than vaccinated ones, whereas both were significantly lower compared to those observed in sera from patients that had been infected and vaccinated. Sera from patients that had been infected possessed higher levels of anti-N antibodies than those that had been infected and vaccinated (Figure 2), possibly due to a protective effect of vaccination that results in asymptomatic infections and low levels of anti-N antibodies. Of note, vaccinated patients had lower levels of anti-N than naive individuals. Overall, these results are consistent with previous reports suggesting that exposure to SARS-CoV-2 antigens by vaccination and infection results in higher levels of anti-SARS-CoV-2 antibodies than vaccination or infection alone [16–17].

We next measured the neutralization activity of each serum sample at a fixed dilution against SARS-CoV-2\(_W\), SARS-CoV-2α, SARS-CoV-2δ, and SARS-CoV-2δ using virus pseudotypes. The efficiency of neutralization varied depending on the SARS-CoV-2 variant tested (Figure 3A), and the immunological history of the patients (Figure 3B). When the
chronological order of appearance of each variant is considered, a pattern of neutralization reduction consistent with antigenic drift emerges. This is illustrated by the ladder-like distribution of the median percentage neutralization (Figure 3A) and becomes even more evident when neutralization levels are compared between SARS-CoV-2\(\text{\(\text{O}\)}\) and all the other variants, as the former, more evolved S, is neutralized less effectively. A similar trend of neutralization reduction is observed between SARS-CoV-2\(\text{\(\text{W}\)}\) and SARS-CoV-2\(\text{\(\text{D}\)}\) in the V and I\(\text{\(V\)}\) groups (Figure 3A). We also observed that virus neutralization efficiency increases depending on the number and type of exposures, irrespective of the variant tested (Figure 3B). As a result, the I\(\text{\(V\)}\) group exhibited the highest neutralization values against all variants (Figure 3B). Supplementary Figure 2 shows differences in virus neutralization due to vaccine type. Within the V group, those that received BNT162b2 (Pfizer/BioNTech) had higher neutralization levels against all SARS-CoV-2 variants than those who received ChAdOx1 (Oxford/AstraZeneca), which was consistent with previously published data [14]. In contrast, no differences in neutralization efficiency against most variants (with the only exception of SARS-CoV-2\(\text{\(\text{D}\)}\)) was observed within the I\(\text{\(V\)}\) group.

To quantify more accurately the neutralizing potency of the antibody-mediated response among the 4 broad groups (N, V, I, I\(\text{\(V\)}\)), we titrated neutralizing antibodies against each variant. Consistent with our previous results, neutralizing titers significantly decreased as SARS-CoV-2 evolved (Figure 4A). Indeed, the aforementioned ladder-like effect was even more evident. Also consistent with our previous results, the number and type of antigen exposure events had a significant impact on virus neutralization titers (Figure 4B). Patients derived from the I\(\text{\(V\)}\) group displayed significantly higher neutralizing antibody titers compared to every other group across all variants (Figure 4B). Supplementary Figure 3 shows the order of infection and vaccination for each patient in the I\(\text{\(V\)}\) group. In turn, infected patients exhibited variable titers against each variant when compared to vaccinated patients: for example, differences between these 2 groups were nonsignificant when SARS-CoV-2\(\text{\(\text{W}\)}\), SARS-CoV-2\(\text{\(\text{D}\)}\), and SARS-CoV-2\(\text{\(\text{D}\)}\) were compared. However, patients from the V group displayed significantly higher antibody titers against SARS-CoV-2\(\text{\(\text{D}\)}\), albeit neutralization efficiency was still very low. Collectively, these results suggest that SARS-CoV-2 antigenic evolution is directional (SARS-CoV-2 evolved to escape antibody-mediated
Figure 2. Concentrations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and nucleocapsid antibodies in samples derived from patients with different histories of SARS-CoV-2 exposure. The name of the antigen is shown at the top of each panel. Patient groups are defined as N, naive; V, vaccinated; I, infected; and Iv, infected and vaccinated. Antibody concentrations are shown in Meso Scale Discovery (MSD) arbitrary units/mL. Box plots display the interquartile range and median values, whiskers display the maximum and minimum values. Significance levels between patient groups were tested using pairwise Wilcoxon test and are shown in bottom panels as connected dot plots.

Figure 3. Neutralizing responses elicited against pseudotyped viruses carrying the spike (S) protein of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants according to patient exposure history to SARS-CoV-2. Sera from patients were grouped based on immunological histories (N, naive; V, vaccinated; I, infected; and Iv, infected and vaccinated). Neutralizing activity was measured using Wuhan, Alpha, Delta, and Omicron S glycoprotein bearing HIV(SARS-CoV-2) pseudotypes and plotted per patient group (A) and per SARS-CoV-2 S variant (B). Neutralization was measured at a fixed dilution (1:50). Each point represents the mean of 2 replicates. Box plots displayed the interquartile range and median values, whiskers display the maximum and minimum values. Significance levels between patient groups or pseudotyped viruses were tested using pairwise Wilcoxon test, and are shown in bottom panels as connected dot plots.
immunity) and that the number and type of exposure events affect the breadth and potency of the antibody-mediated response.

To understand better how humoral immunity is affected by the antigenicity of SARS-CoV-2 variants, we stratified the I and IV groups according to the strains that had infected the patients. This analysis revealed a trend consistent with homologous immunity as sera from patients that had been infected with SARS-CoV-2W, SARS-CoV-2α, or SARS-CoV-2δ displayed highest potency against their infecting variants, albeit the differences were not always statistically significant (Supplementary Figure 4A). Notably, patients that had been vaccinated and infected with SARS-CoV-2δ showed overall the highest neutralization potency against all variants (Supplementary Figure 4B). As this group of patients had been exposed to the most phylogenetically distant antigens (SARS-CoV-2W by vaccination and SARS-CoV-2δ by infection), this result suggests not only that heterologous exposure results in a broader and more effective humoral response but also that the level of antigenic differences between variants affects the potency of the antibody-mediated response. In addition, we observed some differences among patients that had been vaccinated and infected with each SARS-CoV-2 variant: for example, patients that had been infected with SARS-CoV-2α exhibited lower neutralization efficiency against SARS-CoV-2δ than against SARS-CoV-2W or SARS-CoV-2α (Supplementary Figure 4A). Titration of neutralizing antibodies enabled us to quantify neutralization biases towards specific SARS-CoV-2 variants. Generally, patients infected by specific variants exhibited significantly different neutralizing titers against other SARS-CoV-2 variants (Figure 5A and 5B) and this effect was also evident among vaccinated and infected patients. For example, patients infected with SARS-CoV-2δ exhibited high levels of neutralizing antibodies against SARS-CoV-2δ but significantly lower titers against all other variants (Figure 5A), whereas patients infected with SARS-CoV-2W or SARS-CoV-2α displayed similar levels of neutralizing antibodies against SARS-CoV-2W and SARS-CoV-2α but lower levels against SARS-CoV-2δ and even lower against SARS-CoV-2α (Figure 6). Overall, titers in patients that had been infected only were lower than those measured in patients that had been infected and vaccinated (Figure 5A and 5B). The only exception was observed in sera from patients infected with SARS-CoV-2δ, whose neutralizing antibody titers against the
homologous antigen was similar in vaccinated and infected patients (Figure 5B). Neutralizing antibody responses seemed to display immunological preferences: for example, patients that had been vaccinated and infected with SARS-CoV-2δ exhibited significantly higher neutralization levels against SARS-CoV-2W (the vaccine variant) than SARS-CoV-2δ (the infecting variant), suggesting the stimulation of an anamnestic response. In contrast, patients that had been vaccinated but infected with SARS-CoV-2α showed similar neutralizing antibody titers against SARS-CoV-2W and SARS-CoV-2α. Of note, when neutralizing antibody titers were compared across all patient groups, those vaccinated and infected with SARS-CoV-2δ or infected with SARS-CoV-2δ and then vaccinated displayed the highest titers against all variants (Figure 5B), consistent with the notion that immunity conferred via infection and vaccination results in broader and more potent humoral responses.

As the IW group exhibited the highest antibody titers against all variants, we wanted to determine if the order in which patients were exposed to SARS-CoV-2 (either vaccination first or infection first) played any role in the breadth and potency of antibody mediated neutralization. To test this, we focused on the IαV group, which exhibited a similar number of patients that had been either infected first (n = 28) or vaccinated first (n = 41). Sera from patients that had been infected first and then vaccinated exhibited significantly higher neutralization efficiency against every variant (Supplementary Figure 5) and

![Figure 5](https://academic.oup.com/jid/article-lookup/227/1/40/6653591)

**Figure 5.** Neutralizing antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in sera from patients with different histories of SARS-CoV-2 exposure taking into account the infecting SARS-CoV-2 variant: IW, infected with SARS-CoV-2W; Iα, infected with SARS-CoV-2α; Iδ, infected with SARS-CoV-2δ; IWV, infected with SARS-CoV-2W and vaccinated; IαV, infected with SARS-CoV-2α and vaccinated; and IδV, infected with SARS-CoV-2δ and vaccinated. Neutralizing activity was measured using Wuhan, Alpha, Delta, and Omicron spike glycoprotein bearing HIV(SARS-CoV-2) pseudotypes and plotted per patient group (A) and per SARS-CoV-2 S variant (B). Each point represents the mean of 3 replicates. Box plots displayed the interquartile range and median values, whiskers display the maximum and minimum values. Significance levels between patient groups or pseudotyped viruses were tested using pairwise Wilcoxon test and are shown in bottom panels as connected dot plots.
Neutralizing responses against pseudotyped viruses carrying the spike (S) protein of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants were titrated in patients that had been either infected and vaccinated or vaccinated and infected with SARS-CoV-2α (Wuhan). Serum samples were subject to neutralization assays using lentiviruses pseudotyped with the S protein of SARS-CoV-2α (Wuhan), SARS-CoV-2α (Alpha), SARS-CoV-2δ (Delta), or SARS-CoV-2δ (Omicron). Antibody titers were calculated by interpolating the point at which infectivity had been reduced to 50% of the value for the non-serum control samples. Each point represents the mean of 3 replicates, whiskers display the maximum and minimum values. Significance levels between patient groups were tested using pairwise Wilcoxon test and are shown in bottom panels as connected dot plots.

DISCUSSION

Our study shows that the immunological landscape of SARS-CoV-2 is highly heterogeneous and has been shaped by the complex interplay between host immunity and virus evolution. Infection by, or vaccination against, SARS-CoV-2 does not elicit lifelong immunity [18, 19] but instead result in a variety of immune phenotypes, which are likely to influence both transmission dynamics and disease outcomes. We demonstrate that multiple factors influence the breadth and potency of the antibody-mediated response against SARS-CoV-2 and include antigenicity of the exposing pathogen, number of exposures, and exposure type (infection and/or vaccination). While T-cell responses play an important role in SARS-CoV-2 immunity [20], we could not evaluate the impact of cellular-mediated immunity due to the nature of our samples (ie, sera). In line with previous studies, we show that mutations that appeared during SARS-CoV-2 evolution reduce antibody mediated neutralization [21, 22], suggesting that evolution of the spike gene of SARS-CoV-2 is directional and driven by immune selection. This is consistent with reports of reinfections by novel variants [23, 24]. Our results showing that all serum samples exhibited lowest neutralizing activity against pseudoviruses carrying the spike glycoprotein of SARS-CoV-2α (Figure 4A and Figure 5A) support this view. As all currently licensed vaccine preparations express the S glycoprotein of SARS-CoV-2α, it is expected that the risk of reinfections in vaccinated-only individuals increases as SARS-CoV-2 evolves. Similarly, for infected-only individuals, the risk of reinfection will likely increase as the antigenic distance between the viruses involved in primary and secondary infection increases, and thus is a function of time. Furthermore, the breadth and potency of the antibody response will decrease over time as antibody titers wane (Supplementary Figure 6). Our results also show that more exposure events result in broader and more potent antibody-mediated responses (Figure 3B and Figure 4B), and this protective effect is also influenced by the antigenic nature of the viruses involved in the primary infection (or vaccination) and subsequent infections. This finding suggests that updates of the vaccine strains (or development of multivalent vaccines) will improve protection against evolving variants, and also that increased transmission of antigenically divergent SARS-CoV-2 viruses among previously exposed individuals will result in future higher levels of protection. We also show that primary infection followed by vaccination results in more potent humoral responses (Figure 6), which indicates that the type and order of exposure events have a significant impact on the breadth and potency of the antibody mediated response. These findings are consistent with recent reports [15, 16, 25]. In a previous study, we showed that increased disease severity in this patient cohort is associated with higher levels of neutralizing antibodies [11]. Because vaccination reduces the severity of disease presentation, it is possible that in vaccinated individuals there is a weaker stimulation of the immune system during infection and as result a lower antibody response. While it is not advisable to promote the acquisition of SARS-CoV-2 immunity by
natural infection given the risk of severe disease and/or death due to COVID-19 in naive individuals, our results suggest that vaccines based on live-attenuated viruses might provide increased protection.

In summary, our work underscores the complexity of the immunological landscape of SARS-CoV-2. While our results will inform the development of better epidemiological models to predict the future transmission dynamics of SARS-COV-2 [26], further clinical studies are needed to determine the impact of exposure history on disease presentation to prepare better for the future disease burden of COVID-19 as this disease becomes endemic.

**Supplementary Data**

**Supplementary materials** are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copy-edited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

**Acknowledgments.** We thank Massimo Palmarini for scientific advice and the NHS Greater Glasgow and Clyde Biorepository for providing serum samples.

**Financial support.** This work was supported by the Medical Research Council of the United Kingdom (grant number MC_UU_12014/9). Funding to pay the Open Access publication charges for this article was provided by a block grant from United Kingdom Research and Innovation (UKRI).

**Potential conflict of interests.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–33.
2. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 2021; 372:eabg3055.
3. Tagally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021; 592:438–43.
4. Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 2021; 372:815–21.
5. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature 2022; 603:679–86.
6. United Kingdom Government. Coronavirus (COVID-19) in the UK-vaccinations. https://coronavirus.data.gov.uk/details/vaccinations. Accessed 12 April 2022.
7. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfecion associated with emergence of Omicron in South Africa. Science 2022; 376:eabn4947.
8. Pouwels KB, Pritchard E, Matthews PC, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med 2021; 27:2127–35.
9. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021; 39:4423–8.
10. Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 2021; 373:eabj0299.
11. Hughes EC, Amat JAR, Haney J, et al. Severe acute respiratory syndrome coronavirus 2 surveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demographics and healthcare setting. J Infect Dis 2021; 223:971–80.
12. Team RC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2013.
13. Wickham H. Ggplot2: data analysis. New York: Springer, 2016, 189–201.
14. Davis C, Logan N, Tyson G, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathog 2021; 17:e1010022.
15. Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol 2022; 7:eabn8014.
16. Reynolds CJ, Gibbons JM, Pade C, et al. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science 2022; 375:183–92.
17. Walls AC, Sprouse KR, Bowen JE, et al. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. Cell 2022; 185:872–80.e5.
18. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe 2021; 2: e240–9.
19. Thomas SJ, Moreira ED jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med 2021; 385:1761–73.
20. Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol 2022; 23:186–93.
21. Ibarrondo FJ, Hofmann C, Ali A, Ayoub P, Kohn DB, Yang OO. Previous infection combined with vaccination
produces neutralizing antibodies with potency against SARS-CoV-2 variants. mBio 2021; 12:e0265621.
22. Cele S, Jackson I, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 2022; 602:654–6.
23. Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med 2021; 27:2108–10.
24. Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 2021; 599:114–9.
25. Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 2022; 603:488–92.
26. Saad-Roy CM, Wagner CE, Baker RE, et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science 2020; 370:811–8.